Akers Biosciences (NASDAQ:AKER) and Oxford Immunotec Global (NASDAQ:OXFD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Valuation and Earnings
This table compares Akers Biosciences and Oxford Immunotec Global’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Akers Biosciences||$3.93 million||3.02||-$7.36 million||N/A||N/A|
|Oxford Immunotec Global||$103.08 million||3.83||-$32.88 million||($1.36)||-11.02|
This is a summary of recent recommendations and price targets for Akers Biosciences and Oxford Immunotec Global, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oxford Immunotec Global||0||0||2||0||3.00|
Oxford Immunotec Global has a consensus target price of $19.00, indicating a potential upside of 26.75%. Given Oxford Immunotec Global’s higher probable upside, analysts clearly believe Oxford Immunotec Global is more favorable than Akers Biosciences.
This table compares Akers Biosciences and Oxford Immunotec Global’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oxford Immunotec Global||-12.51%||-41.15%||-24.11%|
Insider & Institutional Ownership
50.2% of Akers Biosciences shares are owned by institutional investors. Comparatively, 91.2% of Oxford Immunotec Global shares are owned by institutional investors. 8.9% of Akers Biosciences shares are owned by company insiders. Comparatively, 6.6% of Oxford Immunotec Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Akers Biosciences has a beta of -0.86, suggesting that its stock price is 186% less volatile than the S&P 500. Comparatively, Oxford Immunotec Global has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
Oxford Immunotec Global beats Akers Biosciences on 9 of the 11 factors compared between the two stocks.
Akers Biosciences Company Profile
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.